The Relative Strength (RS) Rating for Stryker entered a new percentile Monday, with a rise from 77 to 81.
This unique rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History shows that the market's biggest winners tend to have an RS Rating of at least 80 in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Stryker has risen more than 5% past a 371.17 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to create a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
Earnings grew 17% last quarter, up from 11% in the prior report. Revenue also increased, from 9% to 12%.
Stryker earns the No. 9 rank among its peers in the Medical-Products industry group. LeMaitre Vascular, Pro-Dex and Insulet are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
